A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2018
At a glance
- Drugs SHP 647 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AIDA
- Sponsors Shire
- 19 Jul 2018 Planned End Date changed from 3 Jun 2025 to 11 Feb 2025.
- 19 Jul 2018 Planned primary completion date changed from 3 Jun 2025 to 11 Feb 2025.
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.